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Brian J. Cole, M.D., M.B.A.Abstract: Orthoregeneration is defined as a solution for orthopaedic conditions that harnesses the benefits of biology to
improve healing, reduce pain, improve function, and optimally, provide an environment for tissue regeneration. Options
include drugs, surgical intervention, scaffolds, biologics as a product of cells, and physical and electro-magnetic stimuli.
The goal of regenerative medicine is to enhance the healing of tissue after musculoskeletal injuries as both isolated
treatment and adjunct to surgical management, using novel therapies to improve recovery and outcomes. Various or-
thopaedic biologics (orthobiologics) have been investigated for the treatment of pathology involving the shoulder
including the rotator cuff tendons, glenohumeral articular cartilage, glenoid labrum, the joint capsule, and bone. Prom-
ising and established treatment modalities include hyaluronic acid (HA); platelet-rich plasma (PRP) and platelet rich
concentrates (PRC); bone marrow aspirate (BMA) comprising mesenchymal stromal cells (MSCs alternatively termed
medicinal signaling cells and frequently, misleadingly labelled “mesenchymal stem cells”); MSC harvested from adipose,
umbilical, or placental sources; factors including vascular endothelial growth factors (VEGF), basic fibroblast growth factor
(FGF), platelet-derived growth factor (PDGF), transforming growth factor-beta (TGFb), bone morphogenic protein (BMP),
and matrix metalloproteinases (MMPs); prolotherapy; pulsed electromagnetic field therapy; microfracture and other
marrow-stimulation techniques; biologic resurfacing using acellular dermal allografts, allograft Achilles tendons, allograft
lateral menisci, fascia lata autografts, and porcine xenografts; osteochondral autograft or allograft); and autologous
chondrocyte implantation (ACI). Studies involving hyaluronic acid, platelet rich plasma, and medicinal signaling cells of
various origin tissues have shown mixed results to-date as isolated treatments and as surgical adjuncts. Despite varied
results thus far, there is great potential for improved efficacy with refinement of current techniques and translation of
burgeoning preclinical work. Level of Evidence: Level V, expert opinion.rthopaedics at Rush, Chicago, Illinois, U.S.A. (N.B.C., B.S.K.,
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ORTHOREGENERATION NETWORK REVIEW: SHOULDER 3201Introduction
njury, disease, degeneration, and other damage toIthe tissues of the musculoskeletal system represent an
immense and timeless burden for humans. The idea of
tissue regeneration has been an aspirational goal to
combat this burden dating back to the earliest civiliza-
tions.1 In the recent past, attempts to harness modern
biological and technological insights have led to a
regenerative medicine revolution.2 “Orthoregeneration”
is a recently suggested term meant to encompass non-
prosthetic procedures (drugs, surgical interventions,
absorbable biomaterials, biologics, and physical and
electromagnetic stimuli) to treat injured, diseased, or
degenerated musculoskeletal tissues. Despite extraordi-
nary advances, there remain many unknowns regarding
these treatments. It is increasingly difficult for medical
professionals, let alone patients, to stay abreast of the
latest evidence and separate fact from fantasy. “Since
2017, the Orthoregeneration Network (ON) has served
as an independent, international, nonprofit foundation
driving development and understanding of new treat-
ment options in the field of orthopaedic tissue regener-
ation. The mission of the ON is to provide guidance,
education, and knowledge for surgeons to improve the
use of tissue regeneration and biologic therapies in
clinical practice.”3 The purpose of this edition of the ON
Foundation: Orthoregeneration Reviews is to provide clini-
cians with an overview and assessment of the latest
clinical evidence regarding regenerative treatments for
ailments of the shoulder.Overview of Orthoregeneration in the
Shoulder
Shoulder pathology is one of the leading causes of
pain and disability across the globe. Although the true
prevalence of shoulder pathology is not known, authors
have reported the annual incidence of shoulder pain in
primary care at 14.7 per 1,000 patients per year with a
lifetime prevalence of up to 70%.4,5 The causes for
shoulder pain and dysfunction are numerous.
Excepting neurologic and/or functional disorders, all
causes can be linked to an insult to, and/or degenera-
tion of, the anatomic components of the shoulder.
Damage to the tendons about the shoulder, chondral
surfaces, subchondral bone, ligaments, and fibro-
cartilage structures (e.g., glenoid labrum) represent a
broad spectrum of interrelated pathologies.6
Young, skeletally immature patients demonstrate a
remarkable capacity for intrinsic healing.7 On the other
end of the spectrum, older adult patients with degen-
erative or traumatic shoulder injuries have experienced
excellent outcomes following prosthetic shoulder
implants.8-10 This leaves a large percentage of the pop-
ulation who have poor intrinsic healing ability but are
not yet optimal candidates for shoulder arthroplasty.Such patients stand to benefit immensely from advances
in orthoregenerative techniques.
Herein, we will review the evidence for biological and
orthoregenerative therapies in both the operative and
nonoperative management of common shoulder pa-
thologies. Specifically, we will focus on clinical evidence
regarding platelet-rich plasma (PRP), hyaluronic acid
(HA)-containing products, medicinal signaling cells
(MSCs) of various cellular origins, and other related
therapies. We will also comment on emerging trends
and future directions in these areas.
Pathology of the Rotator Cuff Tendons
Accounting for upward of 5 million physician visits
per year, rotator cuff disease is one of the most prob-
lematic orthopedic conditions.11,12 Studies suggest at
least 30% of people over the age of 60 will have full-
thickness rotator cuff tears, and many more suffer
from impingement and rotator cuff tendinopathy.13 For
many, these tears remain asymptomatic with little
effect on quality of life; for others, significant pain and
disability occur.
Many factors play a role in rotator cuff pathology.
Mechanical impingement between the greater tuber-
osity of the humerus and underside of the acromion
may initiate the inflammatory cascade, although this
theory of disease is not definitive.14 The rotator cuff’s
vascularity and healing potential are limited,15 partic-
ularly at the anterolateral aspect of the footprint, where
many tears are found or initiated. Suboptimal vascu-
larity also limits access by signaling cells or growth
factors that would otherwise guide a normal healing
response favoring type I collagen produced by teno-
cytes. Whether in the setting of surgical or nonsurgical
management, this can lead to the formation of biome-
chanically inferior fibrotic tissue, which can cause
recurrent injury or poor response to treatment.16-18 The
rationale for biologic treatment of rotator cuff pathol-
ogy, whether through changing the biological or
structural milieu, is to guide the native rotator cuff
away from tendinopathic changes and scar formation in
favor of tenocyte formation and a physiological tendon-
bone interface.
Orthoregenerative Treatments in Nonoperative
Management
Traditional nonoperative management of rotator cuff
disease includes activity modifications, physical ther-
apy, anti-inflammatory medications, and corticosteroid
injections. However, many patients derive limited or
only short-term benefit from these modalities, and
there is significant concern regarding the effects of
repeated use of corticosteroid injections on tendon
health.19,20 Furthermore, whether because of
concomitant health concerns or lifestyle implications,
not all patients are good surgical candidates. For this
3202 N. B. CONDRON ET AL.reason, orthoregenerative techniques have recently
gained popularitydthe three most common of which
include PRP, MSCs, and prolotherapy.
Platelet-rich plasma and related products (platelet-
rich concentrates [PRC]) are derived from an autolo-
gous, concentrated form of platelets and growth factors.
Whole blood samples from the patient are centrifuged
to concentrate the plasma layer, removing the red
blood cell components with or without the white blood
cell layer (buffy coat). The inclusion of the buffy coat
(leukocyte rich) vs. exclusion (leukocyte poor) can be
used for different injection sites depending on the type
of pathology.21 The concentrated delivery of growth
factors that induce cellular migration, attracting various
autologous stem cells and modulating the inflammatory
response, is believed to be the primary mechanism of
action.22,23 The downregulation of specific inflamma-
tory compounds, namely IL-6 and IL-8, has also been
highlighted in the literature.24
Medicinal signaling cells, alternatively termed
mesenchymal stromal cells (frequently and mislead-
ingly referred to as “mesenchymal stem cells”), are
commonly harvested and then concentrated from
either bone marrow, adipose, umbilical, or placental
sources.25,26 These cells have been studied for their
ability to differentiate into target tissues to aid in heal-
ing, while also altering the biological milieu.27 Immu-
nomodulation via suppression of inflammatory T-cells
and monocyte maturation has been suggested.28,29
Recent studies have also highlighted their ability to
express potentially beneficial growth factors, such as
transforming growth factor-b (TGF-b) and vascular
endothelial growth factor (VEGF), both of which can
aid in tissue healing.29
Prolotherapy involves injecting a natural irritant,
often hypertonic dextrose, into the soft tissues to
stimulate an inflammatory response that can trigger
healing in pathologic tissues. Although the mechanism
has not been completely elucidated, it is suggested that
certain irritants can trigger the local release of growth
factors and chemokines that ultimately modulate
inflammation and trigger the production of the appro-
priate connective tissues.30,31
Various Level I randomized controlled studies have
been performed for the aforementioned treatments
(Table 1). The results for PRP for rotator cuff tendinosis
or partial thickness tearing are mixed. In 2013, Kesik-
burum et al. reported no significant difference between
PRP and normal saline injections for any patient-
reported outcome (PRO) measured up to 1 year from
the date of injection.32 Similarly, Nejati et al. reported
in 2016 that PRP was not better than exercise therapy
for any measure after 6 months of therapy.33 However,
Sari et al. recently reported that for rotator cuff tendi-
nosis, corticosteroid injections outperformed PRP for
the visual analogue scale (VAS), American Shoulderand Elbow Surgeon’s score (ASES), and Western
Ontario Rotator Cuff Index (WORC) scores at 3 weeks,
but at 24 weeks, patients who received PRP had better
VAS and WORC scores.34 Concerning partial-thickness
rotator cuff tears, Cai et al. found that PRP was superior
to placebo and hyaluronate injections for Constant
scores after 12 months, while Ilhanli et al. found that,
compared to physical therapy, PRP was superior for
functional scores but not range of motion (ROM).35,36
Only one Level 1 randomized study was identified for
MSCs in the nonoperative treatment of rotator cuff
tears. Centeno et al., in 2020, found that the combined
injection of bone marrow concentrate (BMC), PRP, and
platelet lysate (PL) was superior to exercise programs
alone at 3, 6, 12, and 24 months for pain and func-
tion.37 In a prospective, nonrandomized study by Kim
et al., it was reported that the combination of BMC and
PRP was superior to exercise therapy alone for pain and
function at 3 months for partial-thickness rotator cuff
tears.38
Three Level I studies were identified for the use of
prolotherapy to treat symptomatic supraspinatus tendi-
nosis.39-41 Bertrand et al. reported that dextrose-based
prolotherapy was superior to saline placebo injection
for pain and patient satisfaction after 9 months.39
However, Lin et al. reported that while dextrose prolo-
therapy was superior at 2 weeks for pain and function
compared to saline placebo, this effect waned after 6
weeks.41 Finally, Cole et al. found that glucose-based
prolotherapy was not superior to corticosteroids
regarding pain and function at either 3 or 6 months from
the date of injection.40
Orthoregenerative Treatments in Operative
Management
Orthoregenerative treatments used in the operative
setting are typically designed to augment or enhance
the healing of native tendon to the bone and restore the
physiological enthesis. Animal studies have suggested
that tendon-to-bone healing following rotator cuff
repair is histologically different from the preexisting
enthesis.42 Instead of the normal four transitional zones
between tendon and bone, an abundance of scar tissue
with type III collagen is formed.17 While techniques
using allograft or autograft patches are gaining interest
in the structural augmentation of repair sites,43-45 bio-
logic approaches, including PRP, MSCs, and isolated
growth factors, have been studied for orthoregenerative
potential.46
Platelet-containing plasma derivatives, most notably
PRP, are a popular option for biological augmentation
of rotator cuff repair. As described above, platelets iso-
lated in the plasma layer have been shown to release a
host of cytokines and growth factors that can aid in
tendon healing.47 In addition to modulating the in-
flammatory response, these factors can recruit native











(Y/N) Results SummaryTest Group Control Test Group Control




Nejati et al.33 I 2017 PRP 31 31 PRP (2 injections
over 1 month)





parameters at 1, 3,
and 6 months.






PRP (1 injection) 1. CSI ; 2.
prolotherapy; 3.
lidocaine




the other groups at 6
months.
Cai et al.35 I 2019 PRP, SH 44 (SH); 45
(PRP); 48
(PRP þ SH)
47 SH vs. PRP vs.
PRP þ SH
(4 injections over
4 weeks for each)




PRP, SH, or saline
alone at 12 months.
Ilhanli et al.36 I 2015 PRP 30 32 PRP (3 injections
over 3 weeks)










group at 12 months.
Centeno et al.37 I 2020 BMC þ PRP þ
PL
14 11 BMC þ PRP þ PRP
(1 injection)


























































(Y/N) Results SummaryTest Group Control Test Group Control
Kim et al.38 II 2018 BMC þ PRP 12 12 BMC þ PRP (1
injection)





group at 3 months.
Bertrand et al.39 I 2016 Dextrose
prolotherapy

















injection group at 9
months.
Cole et al.40 I 2018 Glucose
prolotherapy
17 19 25% glucose (1
injection)




Lin et al.41 I 2019 Dextrose
prolotherapy
16 15 40% dextrose (1
injection)





control group at 2
weeks but no
difference at 6 weeks.
ASES, American Shoulder and Elbow Surgeon’s score; BMC, bone marrow concentrate; CSI, corticosteroid injection; DASH, Disabilities of the Arm, Shoulder, and Hand; NPS, numeric pain
scale; PL, platelet lysate; PROs, patient reported outcomes; PRP, platelet rich plasma; ROM, range of motion; PT, physiotherapy; SANE, single assessment numerical evaluation; SH, sodium


































Group Control Test Group Control
Atuna et al.57 I 2013 PRP 14 14 RCR þ PRF injection
intraoperatively
RCR 24 N No significant differences in
PROs between groups.
Castricini et al.58 I 2011 PRP 43 45 RCR þ PRFM incorporated
at repair site
RCR 16 N No significant differences in
PROs between groups, no
significant difference in MRI-
evaluated tendon healing
between groups.
Malavolta et al.59 I 2014 PRP 27 27 RCR þ PRP/autologous
fibrin injection
intraoperatively
RCR 24 Mixed PRP group exhibited
significantly better UCLA
scores compared with control
group at 12 months, all other
PRO measures at all time
points were nonsignificant.
Ruiz-Moneo et al.60 I 2013 PRP 32 31 RCR þ PRP injection
intraoperatively
RCR 12 N No significant differences in
PROs between groups, no
significant difference in MRI-
evaluated tendon healing
between groups.
Wang et al.61 I 2015 PRP 30 30 RCR þ PRP injections
postoperatively at 7 and
14 days
RCR 4 N No significant differences in
PROs, ROM, strength, or
MRI-evaluated tendon
healing between groups.
Weber et al.62 I 2013 PRP 30 30 RCR þ PRFM incorporated
at repair site
RCR 12 N Control group exhibited
significantly better UCLA
scores compared with PRFM
group at 12 months; all other
PROs, ROM, strength, and
MRI-evaluated healing
characteristics at all time
points were nonsignificant.
Zumstein et al.63 I 2016 PRP 17 18 RCR þ L-PRF clot
incorporated at repair
site








24 N No significant differences in
postoperative pain, PROs, or
repair integrity between
groups.
Snow et al.65 I 2020 PRP 40 47 RCR þ LP-PRP injection
postoperatively at 10-14
days
RCR þ saline injection
postoperatively at 10-14
days
12 N No significant differences in
PROs or retear rates as
assessed by MRI between the























































Group Control Test Group Control
Holtby et al.55 I 2016 PRP 41 41 RCR þ PRP/autologous
fibrin injection
intraoperatively
RCR 6 Mixed PRP group reported significantly
less pain and painkiller
consumption compared with
control group within 30 days;




Gumina et al.56 I 2012 P-L gel 39 37 RCR þ P-L gel RCR 13 Mixed No significant differences in
PROs between groups. Repair
integrity significantly better in
P-L group.
Kim et al.66 III 2017 a-MSC 35 35 RCR þ a-MSC/fibrin glue
injection
intraoperatively
RCR 28 Mixed No significant differences in
PROs or ROM between
groups. Presence of retearing
on follow-up MRI
significantly lower in a-MSC
group compared with control.
Hernigou et al.51 III 2014 BMC 45 45 RCR þ BMC injection
intraoperatively
RCR 120 Y BMC group demonstrated
significantly greater healing
rate by 6 months and had




a-MSC, adipose-derived mesenchymal stem cell; BMC, bone marrow concentrate; L-PRF, leucocyte and platelet rich fibrin; MRI, magnetic resonance imaging; P-L, platelet leukocyte; PRF,




































(Y/N) Results SummaryTest Group Control Test Group Control
Centeno et al.88 III 2015 BMC þ PRP þ
PL
N 115 (81 rotator
cuff; 34 GH OA)
n/a BMC þ PRP þ
PL injection








Darrow et al.87 III 2019 WBM or BMC N 50 (18 rotator cuff;
32 GH OA)
n/a WBM or BMC
injection









Zhang et al.83 Meta-analysis
of level I-IV
studies






















progression in 2 of 5
patients at final
follow- up.




































































(Y/N) Results SummaryTest Group Control Test Group Control
Hünnebeck
et al.95




n/a 105 n/a Significant
improvement in
internal rotation































Savoie et al.101 IV 2009 Biologic
resurfacing












Hartzler et al.100 IV 2017 Biologic
resurfacing






















































(Y/N) Results SummaryTest Group Control Test Group Control
Strauss et al.106 IV 2014 Biologic
resurfacing







n/a 34 n/a 51% clinical failure





PROs at final follow-
up compared to
baseline.
Scheibel et al.103 IV 2004 Osteochondral
autograft















changes in 7 of 8
patients.
Riff et al.102 IV 2017 Osteochondral
allograft
Y 18 n/a Osteochondral
allograft to the
humeral head








mean of 25 months
postoperatively.
Gobezie et al.109 IV 2016 Osteochondral
allograft

































































































































































































































































































































































































































































































































































































































































































































































3210 N. B. CONDRON ET AL.stem cells to the repair site and stimulate blood vessel
formation in an otherwise poorly vascularized area.48
Certain growth factors, such as VEGF and hepatocyte
growth factor (HGF), have previously been shown to
guide tenocyte proliferation and increase the produc-
tion of desired structural proteins, including type I
collagen, decorin, aggrecan, and biglycan.49
Medicinal signaling cells can aid in tendon healing by
either differentiating into tenocytes or osteoblasts at the
repair site or guiding such differentiation from native
progenitor cells.50 Prior work has already demonstrated
reduced progenitor cells at the tear site, highlighting the
need for biological augmentation.51 Human MSCs have
been shown in vitro to differentiate into tenocytes in
the appropriate biological milieu.52 Autologous MSCs
can be used either alone or with other growth factor
preparations to guide the rotator cuff repair site toward
the ideal tenogenic or osteogenic lineage.53
Many cytokines and growth factors are active at the
rotator cuff repair site and can be supplemented to aid
in tendon healing. Factors include vascular endothelial
growth factors (VEGF), basic fibroblast growth factor
(FGF), platelet-derived growth factor (PDGF), trans-
forming growth factor-b (TGFb), bone morphogenic
protein (BMP), and matrix metalloproteinases (MMPs).
These factors can increase angiogenesis to the repair
site, increase cellular proliferation or tenocyte differ-
entiation, promote bony incorporation at the tendon-
bone junction, or remodel the tendon repair site
favoring native type I collagen over scar formation.54
Outcomes regarding the use of orthoregenerative
therapies in the operative treatment of rotator cuff repairs
are mixed (Table 2). Holtby et al. found in 2016 that PRP
augmentation for the repair of small or medium-sized
rotator cuff tears helped with short-term perioperative
pain but hadno significant effect onPROs.55Guminaet al.
also reported improved repair integrity, as measured by
magnetic resonance imaging (MRI), in patients treated
intraoperatively with a platelet-leukocyte (P-L) gel.56
However, multiple Level I studies, whether the PRP was
given intraoperatively or at various time intervals post-
operatively, found that PRP had no significant effect on
pain or any patient-reported outcome.18,57-65
Overall, there is a paucity of high-quality studies
evaluating the use of MSCs to augment rotator cuff
repairs. In one, Kim et al. showed MSCs derived from
adipose tissue applied during arthroscopic single-row
rotator cuff repair showed no clinical benefit, but
drastically reduced retear rates at a 10-year follow up.66
Another study by Hernigou et al. also found a signifi-
cant decrease in retear rate, as measured by MRI, after
surgical augmentation with MSCs derived from
concentrated bone marrow.67
There is also a lack of high-quality investigation
evaluating the use of isolated growth factors to
augment rotator cuff repairs in humans. While the
ORTHOREGENERATION NETWORK REVIEW: SHOULDER 3211application of VEGF to rat models of Achilles tendon
repair was demonstrated to improve final tensile
strength, no study has evaluated its use in humans.68
Ide et al. reported that the application of FGF2 to rat
model rotator cuff repairs accelerated bony ingrowth,
but there was no difference in final repaired tendon
strength.69 Similarly, PDGF has been shown to increase
the early tensile strength of rotator cuff repairs in sheep
models, but there was no notable difference in ultimate
tensile strength.70 At this time, the use of isolated
growth factors in the management of rotator cuff in-
juries is aspirational and requires further evaluation.
Articular Cartilage Pathology
Damage to the glenohumeral (GH) articular cartilage
is a relatively common though underinvestigated entity
when compared to similar ailments of the hip and
knee.71,72 Such damage may arise because of degen-
eration (primary arthritic change or secondary
arthropathy), traumatic injury, inflammatory condi-
tions, and/or iatrogenic injuries (prominent hardware
from prior intervention, chondrolysis from intra-
articular pain pumps).73,74 Articular cartilage damage
may be considered in varying degrees, from small,
partial-thickness focal chondral defects up to wide-
spread bipolar osteoarthritis (OA) affecting the sub-
chondral bone.75 Our understanding of the
pathophysiology of articular cartilage damage and
degeneration is evolving.76 The main underlying chal-
lenge is that adult hyaline cartilage has a poor capacity
for intrinsic healing.77 As such, many efforts have been
made to augment cartilage repair and regeneration in
an effort to restore healthy hyaline cartilage. These ef-
forts have mostly focused on aforementioned treat-
ments such as PRP and MSCs.78 For all degrees of
symptomatic chondral pathology, the mainstay of initial
treatment is nonoperative management. Efforts to
augment nonoperative treatment with orthoregener-
ative approaches exist but have not been widely pub-
lished in relation to GH chondral conditions.79
When nonoperative management fails, total shoulder
arthroplasty (TSA) has proven to be an excellent option
for older patients with OA. In younger patients, and/or
in patients with early-stage pathology, reparative and
restorative surgical techniques, such as microfracture,
autologous chondrocyte implantation, and allograft
resurfacing options have been described.73 In an effort
to improve the efficacy of these procedures, many have
proposed the incorporation of biological adjuncts,
though direct evidence is minimal, and most insights
are extrapolated from efforts in other joints.80
Orthoregenerative Treatments in Nonoperative
Management
Classically, nonoperative management for shoulder
cartilage pathology has included activity modification,therapeutic exercise, oral anti-inflammatory medica-
tions, and injectable corticosteroid preparations.
Orthoregenerative treatments may be used as adjuncts
to these conservative measures, with the goal to
engender a physiological healing response within the
chondral tissue.
Viscosupplementationwith exogenous highmolecular-
weight HA compounds has been trialed as a means of
temporizing the degeneration of articular cartilage and
restoring joint homeostasis. Hyaluronic acid is a naturally
occurring molecule in cartilage and synovial fluid, which
plays a role in regulationof the local tissueenvironment.81
In degenerative states, endogenous HA is depolymerized
to a low-molecular weight state, and its beneficial prop-
erties are diminished.82 In 2019, Zhang et al. completed a
meta-analysis on the outcomes of HA injections for GH
OA; they reported on 15 studies involving 1,594 patients
with levelsof evidence ranging fromI to IV (Table3).83For
the HA group, they found a significant pooled average
reduction in VAS pain at 3 and 6 months following in-
jection, as well as improvements on other validated PRO
instruments. However, significant improvements were
also found in the control groups across the included
studies, which included corticosteroid and/or saline in-
jections. These findings indicate that HA viscosupple-
mentation is likely no better than existing treatment
options.
Injectable MSC formulations from various sources are
thought to play a key role in cartilage regeneration,
given their potential for homing, self-renewal, and
release of trophic factors that aid in tissue healing.84
Furthermore, bone marrow aspirate (BMA)-derived
MSC preparations contain anti-inflammatory cytokines
and growth factors that are theorized to intervene in
the cascade of inflammation and catabolism associated
with degenerative cartilage pathology.85,86 No ran-
domized studies of MSC injections for GH cartilage
damage have been published, although a few obser-
vational studies exist. In 2019, Darrow et al. reported
on a cohort of patients treated with one or two in-
jections of autologous bone marrow concentrate (BMC)
or autologous whole bone marrow (WBM) for rotator
cuff pathology or GH OA.87 The OA cohort contained
32 patients evaluated at a mean follow-up of 6 months.
In this group, VAS resting and active pain scores
improved significantly from baseline to final follow-up,
as did scores on an abridged version of the Upper Ex-
tremity Functional Index. The authors reported no
significant differences in outcomes between the rotator
cuff group and the isolated GH OA group. In another
cohort study, Centeno et al. investigated the injection of
BMC combined with PRP and PL into shoulders with
rotator cuff injuries or GH OA.88 Platelet lysate is ob-
tained during the preparation of PRP by recentrifuging
PRP and collecting a layer containing lysed platelets.


































































































































































































































































































































































































































































































































































































































































































































3212 N. B. CONDRON ET AL.factors found in both PL and PRP can augment and
enhance MSC proliferation in vitro.89,90 The authors
evaluated 115 shoulders in 102 distinct patients, of
these, 34 shoulders had isolated GH OA. Between
baseline and final follow-up (7-11 months), disabilities
of the arm, shoulder and hand (DASH), and numeric
pain scale (NPS) ratings improved significantly. No
significant differences were found between the rotator
cuff and isolated GH OA groups. As with the study by
Darrow et al., this study did not include a control group
and, therefore, no definitive conclusions can be made.
Orthoregenerative Treatments in Operative
Management
Given that shoulder arthroplasty may be associated
with suboptimal outcomes in younger patients with
chondral defects or early-stage osteoarthritis,91 the
promise of orthoregenerative surgical intervention is
attractive. At present, there are no high-level studies
examining any orthoregenerative surgical techniques
or adjuncts for GH cartilage pathology.
Microfracture and other marrow-stimulation tech-
niques have been performed for small, contained
chondral lesions and reported in a few case series
(Table 3).92-96 The aim of microfracture surgery is to
stimulate bone marrow elements from the subchondral
bone to deliver MSCs and growth factors to the chon-
dral surface, where they will engender tissue healing
and cartilage repair.97 Despite the theoretical promise of
this technique, the resulting fibrocartilage repair tissue
has been shown to have suboptimal physiological and
mechanical properties compared to native hyaline
articular cartilage.98,99 Although short to mid-term
clinical improvements have been reported following
microfracture for GH chondral lesions, long-term in-
vestigations report relatively high rates of OA progres-
sion and conversion to TSA.95,96
While marrow stimulation techniques are aimed at
repairing small chondral defects, other modalities like
biological resurfacing,100,101 osteochondral grafting
(autograft or allograft),102,103 and autologous chon-
drocyte implantation (ACI),104,105 are intended to
restore articular cartilage in the setting of larger defects.
Biological shoulder resurfacing aims to remove
damaged articular cartilage and replace it with an
interpositional biological graft between the native hu-
meral head (or a prosthetic humeral head) and the
native glenoid. Various graft sources have been
described, including acellular dermal allografts, allograft
Achilles tendons, allograft lateral menisci, fascia lata
autografts, and porcine xenografts, among others.74 In
2009, Savoie et al. reported a case series of 23 patients
treated with a porcine intestinal xenograft patch
(Restore [DePuy Orthopedics, Warsaw, IN]) affixed to
the glenoid surface.101 The authors took samples and
performed histological analyses showing that the patches
ORTHOREGENERATION NETWORK REVIEW: SHOULDER 3213contained viable chondrocytes in a hyaline-like matrix at
time 0, but no follow-up histological data were available.
Clinically, the authors reported a 75% success rate for
the procedure at 3-6 years follow-up, with significant
improvements in ASES, VAS, Constant, Rowe, and
University of California, Los Angeles (UCLA) shoulder
scores. Hartzler et al. reported similar results in their
2017 study of 43 shoulders undergoing arthroscopic
glenoid resurfacing with an acellular dermal allograft
(GraftJacket MaxForce Extreme [Wright Medical,
Arlington, TN], or Arthroflex [Arthrex Inc., Naples,
FL]).100 On the other hand, in 2014, Strauss et al. re-
ported a high rate of clinical failure (51.2%) for either
lateral meniscal allografts or acellular dermal allografts in
biologic glenoid resurfacing among 41 patients followed
for an average of 2.8 years.106 Given the variable out-
comes reported, biologic resurfacing is uncommon in
clinical practice and requires further high-level investi-
gation before conclusive comment on its regenerative
efficacy is possible.
Osteochondral grafts seek to transfer a plug of viable
osteochondral tissue, either from a deceased donor
(allograft) or from a minimally weight-bearing chondral
surface of the patient’s body (autograft) to an area of focal
chondral or osteochondral damage. These techniques are
rarely used in the shoulder, but have shown good results
when applied to defects in the knee.107 Osteochondral
grafts have the biologic advantage of restoring “like to
like,” as they implant a fully functional unit of osteo-
chondral tissue that has the same physiological and me-
chanical properties as the surrounding joint surface. Small
case series by Scheibel et al., evaluating osteochondral
autografts, and Riff et al., evaluating osteochondral allo-
grafts, demonstrated varied results, with significant im-
provements in PROmeasures, but relatively high rates of
OA progression and conversion to TSA.102,103 In 2016,
Gobezie et al. reported on 20 patients undergoing bipolar
osteochondral allografts of the humeral head and glenoid
using an innovative all-arthroscopic technique108 and
found significant improvements in PRO and ROM out-
comes at 2.5-year follow-up with a 15% rate of conver-
sion to arthroplasty.109
Autologous chondrocyte implantation is a cell-based
therapy for focal chondral defects that has mainly
been used for cartilage pathology in the knee, although
a few small investigations into its use in the shoulder
have been reported.104,105 Multiple iterations of ACI
have been described, all of which involve taking a small
biopsy of articular cartilage during an index procedure,
expanding the cells ex vivo over a period of weeks, and
then implanting the expanded cells back into the pa-
tient’s chondral defect during a second procedure.110 In
a small case series by Boehm et al., 7 patients treated
with ACI for chondral defects of the humeral head were
followed for an average of 2.7 years.104 They reported
significant improvement in subjective shoulder value(SSV) scores at final follow-up and no relapse of focal
chondral defects in 4 out of 5 patients who underwent
second look arthroscopy. Although promising, no
conclusions may be drawn, given the small sample size
and observational nature of the investigation. There
have been no clinical studies examining the efficacy of
orthobiological treatments such as PRP and MSCs as
adjuncts in the surgical management of GH pathology.
Other Shoulder Pathologies
Research relating to orthoregenerative treatments for
other shoulder pathologies is similarly scarce. While
labral and bony pathology associated with instability are
common problems that receive much attention, most
efforts in these areas aim at augmenting the pathologic
anatomy in an effort to restore function, rather than
regenerating the native anatomy.111 Although an anal-
ysis of current procedural terminology code usage in a
large database of American hospitals indicated that cli-
nicians are performing PRP injections for patients with
glenoid labral pathology, no clinical investigations into
this practice have been published.112
Recently, some authors have investigated the use of
orthoregenerative treatments in the nonoperative
management of adhesive capsulitis (AC). The patho-
physiology of AC involves inflammatory and fibrotic
processes and cell signaling pathways, ultimately leading
to hardening of the joint capsule, pain, and “frozen
shoulder”.113 Understanding these pathophysiological
underpinnings, several investigators have attempted to
harness the anti-inflammatory properties of PRP in the
treatment of AC (Table 4).114-117 In 2017, Kothari et al.
published results from a randomized study evaluating
PRP vs. corticosteroid injection (CSI) vs. ultrasonic
therapy for the nonoperative treatment of AC.115 They
found that patients in the PRP group had significantly
greater improvements in VAS pain, QuickDASH, and
ROM compared to the CSI and ultrasound groups at 12-
week follow-up. Similarly encouraging short-term
findings were published by Barman et al. in 2019, who
found that patients treated with PRP had greater im-
provements in VAS pain, Shoulder Pain and Disability
Index (SPADI), and ROM at 12 weeks compared to
those treated with CSI.114 Conversely, Thu and col-
leagues reported a randomized trial of PRP injection
versus physiotherapy for AC and found no significant
differences between the groups in VAS pain, DASH
scores, and ROM after 6 weeks.116 Further study in this
area is needed to determine the long-term clinical effi-
cacy of PRP injections, and also to characterize the
physiological reaction to treatment in vivo.
Prospects for the Future
Although much investigation has been performed
regarding orthoregenerative treatments for the rotator
cuff, many unanswered questions remain. Further basic
3214 N. B. CONDRON ET AL.scientific study is necessary to fully understand the bio-
logical underpinnings of both the pathology and the cor-
responding treatments. For example, recent strides have
been made toward a greater understanding of the role of
macrophages in the inflammatory response to tendon
injury. As such, targeted therapeutics that influence this
inflammatory milieu will likely become part of the
armamentarium to combat rotator cuff disease.118
Clinically, additional high-level studies that focus on
refining and standardizing the therapeutic indications,
processing techniques, and timing of treatments are
needed. Furthermore, efforts to augment existing cell-
based therapies, such as BMA and other MSC prepa-
rations, with isolated growth factors may allow their
regenerative potential to be fully harnessed.119
Combining such treatments with structural biological
scaffolds, such as those used in patch-augmented re-
pairs and superior capsular reconstruction may further
enhance their efficacy and improve anatomic results.120
In addition to orthobiological modalities, adjuncts such
as pulsed-electromagnetic field therapy may prove to be
efficacious in promoting the healing and regeneration
of rotator cuff tissue.121 In contrast to the significant
investigation into orthoregenerative treatments for the
rotator cuff tendons, studies involving other commonly
injured tissues of the shoulder are lacking. Investigators
must adapt the promising work that has been under-
taken in other joints in order to address similar pa-
thology in the shoulder.
Conclusion
This reviewhashighlighted the current clinical evidence
for biological and orthoregenerative treatments for ail-
ments of the shoulder. Much of the existing work in this
area is focused on the rotator cuff tendons, with relatively
few efforts directed toward other areas such as articular
cartilage, labral, and bony pathology. Although the early
evidence for treatments such as PRP and MSCs is varied,
further efforts to refine and expandupon thesemodalities
are needed to fully understand and harness the potential
of orthoregeneration for the shoulder.
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